NCT00643643View on ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

June 30, 2003

Study Completion Date

June 30, 2003

Conditions
HIV Infections
Interventions
DRUG

Maraviroc (UK-427,857)

25 mg oral tablet once daily for 10 days

DRUG

Maraviroc (UK-427,857)

50 mg oral tablet twice daily for 10 days

DRUG

Maraviroc (UK-427,857)

100 mg oral tablet twice daily for 10 days

DRUG

Maraviroc (UK-427,857)

300 mg oral tablet twice daily for 10 days

OTHER

Placebo

Matching placebo oral tablet twice daily for 10 days

Trial Locations (6)

50924

Pfizer Investigational Site, Cologne

53105

Pfizer Investigational Site, Bonn

80336

Pfizer Investigational Site, München

3584 CX

Pfizer Investigational Site, Utrecht

NW3 2QG

Pfizer Investigational Site, London

SW10 9NH

Pfizer Investigational Site, London

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

ViiV Healthcare

INDUSTRY

NCT00643643 - Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus | Biotech Hunter | Biotech Hunter